Angiodynamics Stock Story

ANGO
 Stock
  

USD 24.14  0.69  2.94%   

Angiodynamics Tangible Asset Value is quite stable at the moment as compared to the past year. The company's current Tangible Asset Value is estimated at 191.04 Million. Working Capital is expected to rise to about 111.6 M this year, although the value of Net Income Per Employee will most likely fall to (46.5 K). While some baby boomers are getting worried about healthcare space, it is reasonable to outline Angiodynamics. We will evaluate why we are still optimistic in anticipation of a recovery. Here I will also outline some technical and fundamental indicators that Angiodynamics investors should consider in August.
Published over three weeks ago
View all stories for Angiodynamics | View All Stories

What are the odds of Angiodynamics sliding in August?

The company is undervalued at 23.79 per share with modest projections ahead.
The firm shows a Beta (market volatility) of 1.2405, which signifies a somewhat significant risk relative to the market. Let's try to break down what Angiodynamics's beta means in this case. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Angiodynamics will likely underperform. Even though it is essential to pay attention to Angiodynamics historical returns, it is always good to be careful when utilizing equity current trending patterns. Our philosophy in foreseeing any stock's future performance is to check both, its past performance charts as well as the business as a whole, including all available technical indicators. Angiodynamics exposes twenty-eight different technical indicators, which can help you to evaluate its performance. Angiodynamics has an expected return of -0.19%. Please be advised to confirm Angiodynamics value at risk, and the relationship between the jensen alpha and skewness to decide if Angiodynamics performance from the past will be repeated at some point in the near future.

How important is Angiodynamics's Liquidity

Angiodynamics financial leverage refers to using borrowed capital as a funding source to finance Angiodynamics ongoing operations. It is usually used to expand the firm's asset base and generate returns on borrowed capital. Angiodynamics financial leverage is typically calculated by taking the company's all interest-bearing debt and dividing it by total capital. So the higher the debt-to-capital ratio (i.e., financial leverage), the riskier the company. Please check the breakdown between Angiodynamics's total debt and its cash.

How does Angiodynamics utilize its cash?

To perform a cash flow analysis of Angiodynamics, investors first need to understand how to read the cash flow statement. A cash flow statement shows the amount of cash Angiodynamics is receiving and how much cash it distributes out in a given period. The Angiodynamics cash flow statement breaks down these inflows and outflows into different buckets, including operating activities, investing activities, and financing activities.
Angiodynamics Net Cash Flow from Operations is quite stable at the moment as compared to the past year. The company's current value of Net Cash Flow from Operations is estimated at (7.38 Million)

What did Angiodynamics file with SEC?

The SEC filings are financial statements or other formal documents of Angiodynamics that are regularly submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make SEC filings and fintech professionals rely on these filings for information about companies they are evaluating for investment purposes. Please note, most SEC filings are available online through the SEC's EDGAR database.
Please check here for more information.
Please note, although all public domestic companies are required to submit their filings via EDGAR, not all public companies are available through our service. Also, keep in mind that the actual annual reports to Angiodynamics shareholders may or may not be submitted as SEC does not always require it.
12th of July 2022
Financial Statements and Exhibits. Regulation FD Disclosure. Results of Operations and Financial Condition
View
9th of February 2022
Unclassified Corporate Event
View
6th of December 2021
Other Events
View
3rd of November 2021
Submission of Matters to a Vote of Security Holders
View
Please note, although all public domestic companies are required to submit their filings via EDGAR, not all public companies are available through our service. Also, keep in mind that the actual annual reports to Angiodynamics shareholders may or may not be submitted as SEC does not always require it.

Sale by Helsel Dave of 5000 shares of Angiodynamics

Legal trades by Angiodynamics insiders are very common, as founders, directors, or employees of any publicly traded firm often have stock or stock options. These trades are made public in the United States through the filing of Form 4 of the Securities and Exchange Commission. Below entry was recorded recently and is publicly available as an insider trade:
Angiodynamics insider trading alert for sale of common stock by Helsel Dave, SVP Global Operations and R&D, on 1st of August 2022. This event was filed by Angiodynamics Inc with SEC on 2022-08-01. Statement of changes in beneficial ownership - SEC Form 4 [view details]   
Note, although insider trading is legal, in the United States, Canada, Australia, and Germany, for mandatory reporting purposes, corporate insiders are defined as a company's officers, directors, and any beneficial owners of more than 10% of a class of the company's equity securities.

What is driving Angiodynamics Investor Appetite?

Angiodynamics holds a total of thirty-eight million six hundred fifty thousand outstanding shares. The majority of Angiodynamics outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to acquire positions in Angiodynamics to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Angiodynamics. Please pay attention to any change in the institutional holdings of Angiodynamics as this could imply that something significant has changed or about to change at the company. Also note that nearly three hundred eighty-six thousand five hundred invesors are currently shorting Angiodynamics expressing very little confidence in its future performance.
 2019 2020 2021 2022 (projected)
Interest Expense907 K861 K774.9 K795.29 K
Gross Profit150.27 M156.79 M141.11 M140.58 M

Ownership Breakdown

Institutions
96.58%
Retail Investors-1.14
Insiders4.56
Institutions96.58

How will Angiodynamics institutional investors react to the next slide?

Total risk alpha is down to 0.32. It may entail a possible volatility slide. Angiodynamics exhibits very low volatility with skewness of 0.14 and kurtosis of 1.23. However, we advise investors to further study Angiodynamics technical indicators to make sure all market info is available and is reliable. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Angiodynamics' stock risk against market volatility during both bullying and bearish trends. The higher level of volatility that comes with bear markets can directly impact Angiodynamics' stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different stocks as prices fall.

Angiodynamics Implied Volatility

Angiodynamics' implied volatility exposes the market's sentiment of Angiodynamics stock's possible movements over time. However, it does not forecast the overall direction of its price. In a nutshell, if Angiodynamics' implied volatility is high, the market thinks the stock has potential for high price swings in either direction. On the other hand, the low implied volatility suggests that Angiodynamics stock will not fluctuate a lot when Angiodynamics' options are near their expiration.

Our Bottom Line On Angiodynamics

Whereas some other companies in the medical instruments & supplies industry are either recovering or due for a correction, Angiodynamics may not be as strong as the others in terms of longer-term growth potentials. All things considered, as of the 11th of July 2022, we believe that at this point, Angiodynamics is undervalued with very low chance of financial distress within the next 2 years. Our final Buy-Hold-Sell recommendation on the company is Buy.

Editorial Staff

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Vlad Skutelnik do not own shares of Angiodynamics. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to editors@macroaxis.com